Tamaki Y, Ohkubo T, Kobayashi M, Sato K, Kikuya M, Obara T, Metoki H, Asayama K, Hirose T, Totsune K, Suzuki K, Imai Y. Cost-effectiveness of hypertension treatment based on the measurement of ambulatory blood pressure. YAKUGAKU ZASSHI. 2010;130(6):805-820. (in Japanese)

Nakahara N, Kamae I, Inagaki A, Kobayashi M. Analysis of the treatment outcomes for schizophrenia using medical fee receipts. Japanese journal of clinical psychopharmacology. 2010;13(4):775-785.

Inoue S, Okuda S, Yamaguchi T. Socio-economic analysis of edaravone for lacunar infarction. Medicine and Drug Journal. 2009;45(8):111-116.

Saito I, Kobayashi M, Saruta T. Pharmacoeconomic evaluation of antihypertensive therapy in Japan. Prog. Med. 2009;29:376-385. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[25] Pharmacoeconomic evaluation of Rheumatoid Arthritis. Monthly Medical Information Express. 2010;4:76-79. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[24] Pharmacoeconomic evaluation of schizophrenia. Monthly Medical Information Express. 2010;3:96-99. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[23] Pharmacoeconomic evaluation of CKD. Monthly Medical Information Express. 2010;2:90-94. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[22] Pharmacoeconomic evaluation of COPD. Monthly Medical Information Express. 2010;1:76-79. (in Japanese)

Nakahara N,Kobayashi M, Mano T, Nakamura J. System Dynamics Simulation for Acute Schizophrenia Treatment. ISPOR 15th Annual International Meeting, 18 May, 2010, Atlanta, GA, USA. (Poster presentation)

Kobayashi M. German situation. ISPOR Japan Chapter 2009 Annual Meeting. 13 May, 2010, Tokyo, Japan. (Seminar “Economic evaluation in healthcare policy making”) (in Japanese)

Kobayashi M. Medical risk and quantitative approach. Medical risk management. Toshiki M. Japan Medical Publisher, 2006, p.23-45.